

# Christian Kratz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9154154/publications.pdf>

Version: 2024-02-01

83  
papers

7,454  
citations

147566

31  
h-index

62479

80  
g-index

110  
all docs

110  
docs citations

110  
times ranked

9743  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
2	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
3	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
4	Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. <i>Nature Reviews Endocrinology</i> , 2018, 14, 229-249.	4.3	388
5	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
6	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, e38-e45.	3.2	358
7	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium "Care for CMMRD" (C4CMMRD). <i>Journal of Medical Genetics</i> , 2014, 51, 355-365.	1.5	351
8	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , 2018, 19, 785-798.	5.1	268
9	Childhood cancer predisposition syndromes: A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	0.7	200
10	<i>IKZF1</i> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1240-1249.	0.8	194
11	Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. <i>Nature Genetics</i> , 2015, 47, 1020-1029.	9.4	190
12	Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMRD" (C4CMMRD). <i>Journal of Medical Genetics</i> , 2014, 51, 283-293.	1.5	168
13	Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. <i>British Journal of Cancer</i> , 2015, 112, 1392-1397.	2.9	167
14	Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e32-e37.	3.2	157
15	Constitutional mismatch repair-deficiency syndrome. <i>Haematologica</i> , 2010, 95, 699-701.	1.7	141
16	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. <i>Clinical Cancer Research</i> , 2017, 23, e83-e90.	3.2	122
17	Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in <i>DICER1</i> . <i>Journal of Clinical Oncology</i> , 2019, 37, 668-676.	0.8	107
18	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	3.9	104

#	ARTICLE	IF	CITATIONS
19	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e107-e114.	3.2	91
20	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
21	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e123-e132.	3.2	55
22	Analysis of the Li-Fraumeni Spectrum Based on an International Germline <i>TP53</i> Variant Data Set. <i>JAMA Oncology</i> , 2021, 7, 1800.	3.4	55
23	Predisposition to cancer in children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 142-154.	2.7	53
24	The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. <i>Cell Death and Differentiation</i> , 2022, 29, 1071-1073.	5.0	53
25	A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. <i>Familial Cancer</i> , 2017, 16, 67-71.	0.9	52
26	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	3.9	52
27	Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 5-12.	0.3	48
28	Understanding the evolving phenotype of vascular complications in telomere biology disorders. <i>Angiogenesis</i> , 2019, 22, 95-102.	3.7	45
29	Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents – Recommendations of the GPOH-NPC Study Group. <i>Klinische Padiatrie</i> , 2016, 228, 105-112.	0.2	44
30	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. <i>Journal of Medical Genetics</i> , 2019, 56, 53-62.	1.5	40
31	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	0.8	40
32	A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes. <i>Human Mutation</i> , 2019, 40, 649-655.	1.1	30
33	Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. <i>British Journal of Cancer</i> , 2020, 123, 619-623.	2.9	30
34	Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. <i>European Journal of Cancer</i> , 2021, 153, 51-63.	1.3	25
35	Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group. <i>European Journal of Medical Genetics</i> , 2016, 59, 111-115.	0.7	23
36	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020, 12, 611.	1.7	23

#	ARTICLE	IF	CITATIONS
37	Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact. <i>European Journal of Medical Genetics</i> , 2016, 59, 143-151.	0.7	22
38	Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). <i>Familial Cancer</i> , 2021, 20, 317-325.	0.9	22
39	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). <i>European Journal of Human Genetics</i> , 2018, 26, 1417-1423.	1.4	20
40	High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers. <i>Journal of Medical Genetics</i> , 2020, 57, 269-273.	1.5	20
41	Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	2.0	20
42	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. <i>Familial Cancer</i> , 2021, 20, 305-316.	0.9	20
43	Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1677-1679.	0.8	18
44	Prognostic impact of IKZF1 deletions in association with vincristine+dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. <i>Leukemia</i> , 2017, 31, 1840-1842.	3.3	18
45	TIM3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28302.	0.8	17
46	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome. <i>Leukemia</i> , 2021, 35, 1475-1479.	3.3	17
47	Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia: A Nationwide Register-Based Cohort Study in Germany. <i>Journal of Clinical Oncology</i> , 2022, 40, 32-39.	0.8	17
48	Need for a precise molecular diagnosis in Beckwith-Wiedemann and Silver-Russell syndrome: what has to be considered and why it is important. <i>Journal of Molecular Medicine</i> , 2020, 98, 1447-1455.	1.7	15
49	Effective identification of cancer predisposition syndromes in children with cancer employing a questionnaire. <i>Familial Cancer</i> , 2021, 20, 257-262.	0.9	15
50	Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. <i>Journal of Pediatrics</i> , 2021, 230, 55-61.e4.	0.9	14
51	A novel classification of hematologic conditions in patients with Fanconi anemia. <i>Haematologica</i> , 2021, 106, 3000-3003.	1.7	14
52	Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms. <i>Klinische Padiatrie</i> , 2017, 229, 329-334.	0.2	13
53	Revisiting Wilms tumour surveillance in Beckwith-Wiedemann syndrome with IC2 methylation loss, reply. <i>European Journal of Human Genetics</i> , 2018, 26, 471-472.	1.4	13
54	Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. <i>Familial Cancer</i> , 2021, 20, 327-336.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2650-2657.	3.3	13
56	PMS2 inactivation by a complex rearrangement involving an HERV retroelement and the inverted 100-kb duplication on 7p22.1. <i>European Journal of Human Genetics</i> , 2016, 24, 1598-1604.	1.4	9
57	Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features. <i>Familial Cancer</i> , 2021, 20, 273-277.	0.9	9
58	Cancer surveillance for individuals with Li-Fraumeni syndrome. <i>European Journal of Human Genetics</i> , 2020, 28, 1481-1482.	1.4	7
59	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 927-935.	1.1	7
60	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	1.7	7
61	Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany: A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 7747-7758.	1.3	7
62	Congenital Transcobalamin II Deficiency: A Rare Entity with a Broad Differential. <i>Klinische Padiatrie</i> , 2017, 229, 355-357.	0.2	6
63	KBG syndrome patient due to 16q24.3 microdeletion presenting with a paratesticular rhabdoid tumor: Coincidence or cancer predisposition?. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 1449-1454.	0.7	6
64	<i>TP53</i> , <i>ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e402-e405.	1.7	6
65	Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies. <i>European Journal of Human Genetics</i> , 2016, 24, 3-4.	1.4	5
66	Down syndrome, RASopathies, and other rare syndromes. <i>Seminars in Hematology</i> , 2017, 54, 123-128.	1.8	5
67	Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer. <i>Familial Cancer</i> , 2021, 20, 289-291.	0.9	5
68	Unusual phenotypes in patients with a pathogenic germline variant in <i>DICER1</i> . <i>Familial Cancer</i> , 2021, , 1.	0.9	5
69	Clinical spectrum and management of imprinting disorders. <i>Medizinische Genetik</i> , 2020, 32, 321-334.	0.1	5
70	The Strong Prognostic Effect of Concurrent Deletions of <i>IKZF1</i> and <i>PAX5</i> , <i>CDKN2A</i> , <i>CDKN2B</i> or <i>PAR1</i> in the Absence of <i>ERG</i> Deletions ( <i>IKZF1</i> plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. <i>Blood</i> , 2014, 124, 131-131.	0.6	4
71	Constitutional or biallelic? Settling on a name for a recessively inherited cancer susceptibility syndrome. <i>Journal of Medical Genetics</i> , 2016, 53, 226-226.	1.5	3
72	Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study. <i>BMC Pediatrics</i> , 2020, 20, 48.	0.7	3

#	ARTICLE	IF	CITATIONS
73	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1277-1283.	2.1	3
74	Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 4815.	1.0	2
75	SCT for Secondary AML in a Patient with Glycogen Storage Disease Type 1b. <i>Blood</i> , 2012, 120, 4402-4402.	0.6	1
76	TP53, ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 884-884.	0.6	1
77	Inherited Disorders of the Ras-MAPK Pathway. <i>Blood</i> , 2018, 132, SCI-41-SCI-41.	0.6	1
78	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	0.6	1
79	Correction: Congenital Transcobalamin II Deficiency: A Rare Entity with a Broad Differential. <i>Klinische Padiatrie</i> , 2017, 229, e1-e1.	0.2	0
80	First Report of Glioblastoma and Associated PNKP Mutation. <i>Neuropediatrics</i> , 2021, 52, .	0.3	0
81	Corrigendum to: Clinical spectrum and management of imprinting disorders. <i>Medizinische Genetik</i> , 2021, 33, 61-63.	0.1	0
82	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and <i>in vivo</i> validation. <i>Neuro-Oncology</i> , 2022, 24, i168-i169.	0.6	0
83	ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations and TP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i4-i4.	0.6	0